Research & Literature

Advance care planning: Let's start sooner.

Howard M, Bernard C, Tan A, et al.

Canadian family physician Medecin de famille canadien 2015; (61(8)):663-5.

Advanced case of glioblastoma multiforme and pregnancy. An ethical dilemma.

Al-Rasheedy IM, Al-Hameed FM

Neurosciences (Riyadh, Saudi Arabia) 2015; (20(4)):388-91 doi:10.17712/nsj.2015.4.20150069.

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.

Yang P, Zhang W, Wang Y, et al.

Oncotarget 2015; (6(38)):40896-906 doi:10.18632/oncotarget.5683.

Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.

Younis SG, Khedr RA, El-Shorbagy SH

Journal of the Egyptian National Cancer Institute 2016; (28(1)):23-30.

Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients.

Yoo RE, Choi SH

Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine 2016; (15(2)):165-77 doi:10.2463/mrms.rev.2015-0053.

[Treatment of recurrent glioblastoma with single-agent bevacizumab].

Sinkó D, Nemeskéri C

Orvosi hetilap 2016; (157(13)):500-3 doi:10.1556/650.2015.30395.

Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.

Yoon RG, Kim HS, Paik W, et al.

European radiology 2017; (27(1)):255-266 doi:10.1007/s00330-016-4346-y.

Current management of low-grade gliomas.

Hottinger AF, Hegi ME, Baumert BG

Current opinion in neurology 2016; (29(6)):782-788 doi:10.1097/WCO.0000000000000390.

Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.

Lombardi G, Pambuku A, Bellu L, et al.

Critical reviews in oncology/hematology 2017; (111()):94-102 doi:10.1016/j.critrevonc.2017.01.018.

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Perry JR, Laperriere N, O'Callaghan CJ, et al.

The New England journal of medicine 2017; (376(11)):1027-1037 doi:10.1056/NEJMoa1611977.

Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.

Skardelly M, Dangel E, Gohde J, et al.

The oncologist 2017; (22(5)):570-575 doi:10.1634/theoncologist.2016-0347.

Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.

Azoulay M, Santos F, Shenouda G, et al.

Journal of neuro-oncology 2017; (132(3)):419-426 doi:10.1007/s11060-017-2383-2.

Prognostic Implications of Extent of Resection in Glioblastoma: Analysis from a Large Database.

Trifiletti DM, Alonso C, Grover S, et al.

World neurosurgery 2017; (103()):330-340 doi:10.1016/j.wneu.2017.04.035.

Pyogenic brain abscess with atypical features resembling glioblastoma in advanced MRI imaging.

Hakim A, Oertel M, Wiest R

Radiology case reports 2017; (12(2)):365-370 doi:10.1016/j.radcr.2016.12.007.

Contrast-enhanced MR Imaging versus Contrast-enhanced US: A Comparison in Glioblastoma Surgery by Using Intraoperative Fusion Imaging.

Prada F, Vitale V, Del Bene M, et al.

Radiology 2017; (285(1)):242-249 doi:10.1148/radiol.2017161206.

Response Assessment in Neuro-Oncology Clinical Trials.

Wen PY, Chang SM, Van den Bent MJ, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(21)):2439-2449 doi:10.1200/JCO.2017.72.7511.

Pseudoprogression after glioma therapy: an update.

Galldiks N, Kocher M, Langen KJ

Expert review of neurotherapeutics 2017; (17(11)):1109-1115 doi:10.1080/14737175.2017.1375405.

Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.

Xi YB, Guo F, Xu ZL, et al.

Journal of magnetic resonance imaging : JMRI 2018; (47(5)):1380-1387 doi:10.1002/jmri.25860.

Treatment of Glioblastoma in Older Adults.

Braun K, Ahluwalia MS

Current oncology reports 2017; (19(12)):81 doi:10.1007/s11912-017-0644-z.

Pseudoprogression as an adverse event of glioblastoma therapy.

Balaña C, Capellades J, Pineda E, et al.

Cancer medicine 2017; (6(12)):2858-2866 doi:10.1002/cam4.1242.

Advance Directives for Dementia: Meeting a Unique Challenge.

Gaster B, Larson EB, Curtis JR

JAMA 2017; (318(22)):2175-2176 doi:10.1001/jama.2017.16473.

Neuroimaging of Brain Tumors: Pseudoprogression, Pseudoresponse, and Delayed Effects of Chemotherapy and Radiation.

Dietrich J, Winter SF, Klein JP

Seminars in neurology 2017; (37(5)):589-596 doi:10.1055/s-0037-1608657.

Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme.

Jeong DE, Woo SR, Nam H, et al.

Oncology letters 2017; (14(6)):8213-8219 doi:10.3892/ol.2017.7196.

An Examination of the Role of Supramaximal Resection of Temporal Lobe Glioblastoma Multiforme.

Glenn CA, Baker CM, Conner AK, et al.

World neurosurgery 2018; (114()):e747-e755 doi:10.1016/j.wneu.2018.03.072.

Current state of immunotherapy for glioblastoma.

Lim M, Xia Y, Bettegowda C, Weller M

Nature reviews. Clinical oncology 2018; (15(7)):422-442 doi:10.1038/s41571-018-0003-5.

The impact of traveling distance and hospital volume on post-surgical outcomes for patients with glioblastoma.

Lopez Ramos C, Brandel MG, Steinberg JA, et al.

Journal of neuro-oncology 2019; (141(1)):159-166 doi:10.1007/s11060-018-03022-w.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, et al.

The Cochrane database of systematic reviews 2018; (11()):CD008218 doi:10.1002/14651858.CD008218.pub4.

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.

Lombardi G, De Salvo GL, Brandes AA, et al.

The Lancet. Oncology 2019; (20(1)):110-119 doi:10.1016/S1470-2045(18)30675-2.

Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis.

Kazmi F, Soon YY, Leong YH, et al.

Journal of neuro-oncology 2019; (142(1)):79-90 doi:10.1007/s11060-018-03064-0.

Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques.

van Dijken BRJ, van Laar PJ, Smits M, et al.

Journal of magnetic resonance imaging : JMRI 2019; (49(1)):11-22 doi:10.1002/jmri.26306.

Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis.

Körber V, Yang J, Barah P, et al.

Cancer cell 2019; (35(4)):692-704.e12 doi:10.1016/j.ccell.2019.02.007.

Herpes Simplex Virus 1 encephalitis with normal cerebrospinal fluid after brain radiotherapy in a patient with glioblastoma. A case report and review of literature.

Mutti C, Curti E, Ciliento R, et al.

Acta bio-medica : Atenei Parmensis 2019; (90(2)):327-330 doi:10.23750/abm.v90i2.8218.

Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature.

Montemurro N

Journal of neurological surgery. Part A, Central European neurosurgery 2020; (81(1)):64-70 doi:10.1055/s-0039-1688911.

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.

Ohno M, Miyakita Y, Takahashi M, et al.

Radiation oncology (London, England) 2019; (14(1)):200 doi:10.1186/s13014-019-1389-7.

The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis.

Zhou M, Niu C, Jia L, He H

Medicine 2019; (98(50)):e18194 doi:10.1097/MD.0000000000018194.

Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.

Kim CY, Paek SH, Nam DH, et al.

Journal of neuro-oncology 2020; (146(3)):399-406 doi:10.1007/s11060-019-03361-2.

Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.

Wu H, Tong H, Du X, et al.

European radiology 2020; (30(6)):3254-3265 doi:10.1007/s00330-020-06702-2.

Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.

Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, et al.

Journal of neuro-oncology 2020; (147(2)):297-307 doi:10.1007/s11060-020-03451-6.

Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.

Gonçalves FG, Chawla S, Mohan S

Journal of magnetic resonance imaging : JMRI 2020; (52(4)):978-997 doi:10.1002/jmri.27105.

Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the national cancer database from 2004 to 2013.

Zreik J, Moinuddin FM, Yolcu YU, et al.

Journal of neuro-oncology 2020; (148(1)):69-79 doi:10.1007/s11060-020-03469-w.

Re-Irradiation and Its Contribution to Good Prognosis in Recurrent Glioblastoma Patients.

Kim MS, Lim J, Shin HS, Cho KG

Brain tumor research and treatment 2020; (8(1)):29-35 doi:10.14791/btrt.2020.8.e10.

Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series.

Gesundheit B, Ben-David E, Posen Y, et al.

Frontiers in oncology 2020; (10()):702 doi:10.3389/fonc.2020.00702.

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.

Galbraith K, Kumar A, Abdullah KG, et al.

Journal of neuropathology and experimental neurology 2020; (79(8)):843-854 doi:10.1093/jnen/nlaa059.

Palliative Care in High-Grade Glioma: A Review.

Crooms RC, Goldstein NE, Diamond EL, Vickrey BG

Brain sciences 2020; (10(10)) doi:10.3390/brainsci10100723.

The many faces of glioblastoma: Pictorial review of atypical imaging features.

Khandwala K, Mubarak F, Minhas K

The neuroradiology journal 2021; (34(1)):33-41 doi:10.1177/1971400920965970.

TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma.

Kikuchi Z, Shibahara I, Yamaki T, et al.

Neuro-oncology advances 2020; (2(1)):vdaa114 doi:10.1093/noajnl/vdaa114.

Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?

Riess C, Irmscher N, Salewski I, et al.

Cancer metastasis reviews 2021; (40(1)):153-171 doi:10.1007/s10555-020-09940-4.

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.

Mata DA, Benhamida JK, Lin AL, et al.

Acta neuropathologica communications 2020; (8(1)):186 doi:10.1186/s40478-020-01058-6.

Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?

Weller M, Reifenberger G

Current opinion in neurology 2020; (33(6)):701-706 doi:10.1097/WCO.0000000000000871.

Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management.

Paranthaman S, Goravinahalli Shivananjegowda M, Mahadev M, et al.

Pharmaceutics 2020; (12(12)) doi:10.3390/pharmaceutics12121198.

Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.

Lee D, Riestenberg RA, Haskell-Mendoza A, Bloch O

Journal of neuro-oncology 2021; (152(1)):89-98 doi:10.1007/s11060-020-03677-4.

IDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions.

Dono A, Ballester LY, Primdahl D, et al.

Current oncology reports 2021; (23(2)):20 doi:10.1007/s11912-020-01006-6.

Advance Care Planning and End-Of-Life Communications: Practical Tips for Oncology Advanced Practitioners.

Goswami P

Journal of the advanced practitioner in oncology 2021; (12(1)):89-95 doi:10.6004/jadpro.2021.12.1.7.

Tumor Treating Fields : Additional Mechanisms and Additional Applications.

Kumaria A

Journal of Korean Neurosurgical Society 2021; (64(3)):469-471 doi:10.3340/jkns.2020.0188.

Pre-Surgery Cognitive Performance and Voxel-Based Lesion-Symptom Mapping in Patients with Left High-Grade Glioma.

Guarracino I, Ius T, Baiano C, et al.

Cancers 2021; (13(6)) doi:10.3390/cancers13061467.

Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma.

Schritz A, Aouali N, Fischer A, et al.

Neuro-oncology advances 2021; (3(1)):vdab052 doi:10.1093/noajnl/vdab052.

TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.

Fujimoto K, Arita H, Satomi K, et al.

Acta neuropathologica 2021; (142(2)):323-338 doi:10.1007/s00401-021-02337-9.

Handcrafted and Deep Learning-Based Radiomic Models Can Distinguish GBM from Brain Metastasis.

Liu Z, Jiang Z, Meng L, et al.

Journal of oncology 2021; (2021()):5518717 doi:10.1155/2021/5518717.

The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.

Kurdi M, Shafique Butt N, Baeesa S, et al.

Pathology oncology research : POR 2021; (27()):1609778 doi:10.3389/pore.2021.1609778.

Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials.

Chen W, Liu D, Liu P, et al.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2021; (33(3)):417-432 doi:10.21147/j.issn.1000-9604.2021.03.12.

Prognostic and Predictive Biomarkers in Gliomas.

Śledzińska P, Bebyn MG, Furtak J, et al.

International journal of molecular sciences 2021; (22(19)) doi:10.3390/ijms221910373.

Pseudoprogression in lung cancer patients treated with immunotherapy.

Chen MY, Zeng YC

Critical reviews in oncology/hematology 2022; (169()):103531 doi:10.1016/j.critrevonc.2021.103531.

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?

Teske N, Karschnia P, Weller J, et al.

Journal of neuro-oncology 2022; (156(2)):317-327 doi:10.1007/s11060-021-03912-6.

Sociocognitive Functioning and Psychosocial Burden in Patients with Brain Tumors.

Pertz M, Schlegel U, Thoma P

Cancers 2022; (14(3)) doi:10.3390/cancers14030767.

Reclassification of Glioblastoma Multiforme According to the 2021 World Health Organization Classification of Central Nervous System Tumors: A Single Institution Report and Practical Significance.

Stoyanov GS, Lyutfi E, Georgieva R, et al.

Cureus 2022; (14(2)):e21822 doi:10.7759/cureus.21822.

Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials.

Perlow HK, Prasad RN, Yang M, et al.

Cancer 2022; (128(12)):2367-2374 doi:10.1002/cncr.34192.

Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.

Zhang Y, Lucas CG, Young JS, et al.

Neuro-oncology 2022; (24(10)):1749-1762 doi:10.1093/neuonc/noac089.

Association between surgical volume and outcomes after craniotomy for brain tumor removal: A South Korean nationwide cohort study.

Choi HR, Song IA, Oh TK

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; (100()):75-81 doi:10.1016/j.jocn.2022.04.007.

Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).

Khabibov M, Garifullin A, Boumber Y, et al.

International journal of oncology 2022; (60(6)).

Survival after reoperation for recurrent glioblastoma multiforme: A prospective study.

Furtak J, Kwiatkowski A, Śledzińska P, et al.

Surgical oncology 2022; (42()):101771 doi:10.1016/j.suronc.2022.101771.

Optimal managements of elderly patients with glioblastoma.

Arakawa Y, Mineharu Y, Uto M, Mizowaki T

Japanese journal of clinical oncology 2022; (52(8)):833-842 doi:10.1093/jjco/hyac075.

Glioblastoma 20 years after a nail gun trauma: A risk factor?

Finneran MM, Young M, Joyce L, Nardone EM

Clinical case reports 2022; (10(6)):e05927 doi:10.1002/ccr3.5927.

The Routine Application of Tumor-Treating Fields in the Treatment of Glioblastoma WHO° IV.

Krigers A, Pinggera D, Demetz M, et al.

Frontiers in neurology 2022; (13()):900377 doi:10.3389/fneur.2022.900377.

Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.

Kurokawa R, Kurokawa M, Baba A, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2022; (42(5)):1474-1493 doi:10.1148/rg.210236.

Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.

Todo T, Ito H, Ino Y, et al.

Nature medicine 2022; (28(8)):1630-1639 doi:10.1038/s41591-022-01897-x.

The Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in the Differentiation of Pseudoprogression and Recurrence of Intracranial Gliomas.

Jing H, Yan X, Li J, et al.

Contrast media & molecular imaging 2022; (2022()):5680522 doi:10.1155/2022/5680522.

Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI.

Cai X, Chen Z, Chang B, et al.

Frontiers in oncology 2022; (12()):937345 doi:10.3389/fonc.2022.937345.

World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.

Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN

JAMA oncology 2022; (8(10)):1493-1501 doi:10.1001/jamaoncol.2022.2844.

MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study.

Szylberg M, Sokal P, Śledzińska P, et al.

Biomedicines 2022; (10(8)) doi:10.3390/biomedicines10082030.

The Role of Apparent Diffusion Coefficient Values in Glioblastoma: Differentiating Tumor Progression Versus Treatment-Related Changes.

Kamali A, Gandhi A, Nunez LC, et al.

Journal of computer assisted tomography 2022; (46(6)):923-928 doi:10.1097/RCT.0000000000001373.

Pre-operative MRI radiomics model non-invasively predicts key genomic markers and survival in glioblastoma patients.

Pease M, Gersey ZC, Ak M, et al.

Journal of neuro-oncology 2022; (160(1)):253-263 doi:10.1007/s11060-022-04150-0.

Comparative outcomes of short-term and long-term fractionation with temozolomide in older glioblastoma patients: Single-center experience.

Uysal B, Gamsiz H, Sager O, et al.

Journal of cancer research and therapeutics 2022; (18(6)):1610-1615 doi:10.4103/jcrt.JCRT_984_20.

Effect of Extent of Resection on Survival of Patients with Glioblastoma, IDH-Wild-Type, WHO Grade 4 (WHO 2021): Systematic Review and Meta-Analysis.

Jusue-Torres I, Lee J, Germanwala AV, et al.

World neurosurgery 2023; (171()):e524-e532 doi:10.1016/j.wneu.2022.12.052.

Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma.

Sekely A, Bernstein LJ, Campbell KL, et al.

Neuro-oncology practice 2023; (10(1)):89-96 doi:10.1093/nop/npac068.

The emotional journey of neuro-oncology: Primary brain tumor patients share their experience during this life-threatening disease.

Loughan AR, Reid M, Willis KD, et al.

Neuro-oncology practice 2023; (10(1)):71-78 doi:10.1093/nop/npac067.

Plasma nanoDSF Denaturation Profile at Baseline Is Predictive of Glioblastoma EGFR Status.

Eyraud R, Ayache S, Tsvetkov PO, et al.

Cancers 2023; (15(3)) doi:10.3390/cancers15030760.

Effects of gross total resection and subtotal resection on survival outcomes of glioma patients: a meta-analysis.

Shi Y, Liu C, Cheng D, et al.

Biotechnology & genetic engineering reviews 2023; (39(2)):1321-1344 doi:10.1080/02648725.2023.2177034.

MALDI Imaging Mass Spectrometry of High-Grade Gliomas: A Review of Recent Progress and Future Perspective.

Rončević A, Koruga N, Soldo Koruga A, et al.

Current issues in molecular biology 2023; (45(2)):838-851 doi:10.3390/cimb45020055.

Epilepsy and brain tumors: Two sides of the same coin.

Aronica E, Ciusani E, Coppola A, et al.

Journal of the neurological sciences 2023; (446()):120584 doi:10.1016/j.jns.2023.120584.

Parent Preferences and Experiences in Advance Care Planning in the Neonatal Intensive Care Unit.

Lin M, Williams D, Vitcov G, et al.

American journal of perinatology 2024; (41(S 01)):e1783-e1791 doi:10.1055/s-0043-1768960.

Do Multidisciplinary Tumor Board Discussions Correlate With Increase in 5-Year Survival? A Meta-Analysis Study.

Algwaiz G, Salam Y, Bustami R, et al.

Global journal on quality and safety in healthcare 2021; (4(1)):3-10 doi:10.36401/JQSH-20-23.

Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.

Ballo MT, Conlon P, Lavy-Shahaf G, et al.

Journal of neuro-oncology 2023; (164(1)):1-9 doi:10.1007/s11060-023-04348-w.

Peritumoral Radiomics for Identification of Telomerase Reverse Transcriptase Promoter Mutation in Patients With Glioblastoma Based on Preoperative MRI.

Zhang H, Zhou B, Zhang H, et al.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2024; (75(1)):143-152 doi:10.1177/08465371231183309.

Editorial for "Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells".

Kolothara Unnikrishnan M, Schmidt MHH

Cancers 2023; (15(15)) doi:10.3390/cancers15153830.

Proteomic and metabolomic analyses illustrate the mechanisms of expression of the O6 -methylguanine-DNA methyltransferase gene in glioblastoma.

Chen X, Sun J, Li Y, et al.

CNS neuroscience & therapeutics 2024; (30(2)):e14415 doi:10.1111/cns.14415.

The Role of Ketone Bodies in Treatment Individualization of Glioblastoma Patients.

Tamas C, Tamas F, Kovecsi A, et al.

Brain sciences 2023; (13(9)) doi:10.3390/brainsci13091307.

Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings.

Begagić E, Pugonja R, Bečulić H, et al.

Brain sciences 2023; (13(11)) doi:10.3390/brainsci13111602.

5-aminolevulinic enhanced brain lesions mimic glioblastoma: A case report and literature review.

Chang CY, Chen CC

Medicine 2024; (103(1)):e34518 doi:10.1097/MD.0000000000034518.

Epigenetic modification and characterization of the MGMT promoter region using CRISPRoff in glioblastoma cells.

Weber R, Weller M, Reifenberger G, Vasella F

Frontiers in oncology 2024; (14()):1342114 doi:10.3389/fonc.2024.1342114.

Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma.

Agarwal A, Edgar MA, Desai A, et al.

AJNR. American journal of neuroradiology 2024; (45(8)):1006-1012 doi:10.3174/ajnr.A8225.

Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.

Bagley SJ, Logun M, Fraietta JA, et al.

Nature medicine 2024; (30(5)):1320-1329 doi:10.1038/s41591-024-02893-z.

Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors.

Wang J, Du Q, Chen J, et al.

Frontiers in oncology 2024; (14()):1345190 doi:10.3389/fonc.2024.1345190.

Long-Term Outcomes of Surgery and Radiation Treatment for Adult Patients with Craniopharyngioma.

Poiset SJ, Song A, In Yoon H, et al.

World neurosurgery 2024; (187()):e852-e859 doi:10.1016/j.wneu.2024.04.177.

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.

Dipasquale A, Franceschi E, Giordano L, et al.

ESMO open 2024; (9(6)):103485 doi:10.1016/j.esmoop.2024.103485.

"Life…Gets Turned Upside-Down…" Opportunities to Improve Palliative Care for High-Grade Glioma.

Crooms RC, Nnemnbeng JF, Taylor JW, et al.

Journal of pain and symptom management 2024; (68(3)):272-281.e2 doi:10.1016/j.jpainsymman.2024.06.001.

'It was never about me': A qualitative inquiry into the experiences of psychological support and perceived support needs of family caregivers of people with high-grade glioma.

Lion KM, Jamieson A, Billin A, et al.

Palliative medicine 2024; (38(8)):874-883 doi:10.1177/02692163241261211.

Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma.

Zemskova O, Yu NY, Leppert J, Rades D

Anticancer research 2024; (44(7)):3059-3066 doi:10.21873/anticanres.17119.

Perioperative imaging predictors of tumor progression and pseudoprogression: A systematic review.

Librizzi G, Lombardi G, Bertoldo A, Manara R

Critical reviews in oncology/hematology 2024; (202()):104445 doi:10.1016/j.critrevonc.2024.104445.

RANO 2.0 criteria: concepts applicable to the neuroradiologist's clinical practice.

Sanvito F, Castellano A, Cloughesy TF, et al.

Current opinion in oncology 2024; (36(6)):536-544 doi:10.1097/CCO.0000000000001077.

Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.

Guo G, Zhang Z, Zhang J, et al.

Cancer immunology, immunotherapy : CII 2024; (73(10)):193 doi:10.1007/s00262-024-03774-7.

Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.

Kuehn JC, Metzger P, Neidert N, et al.

NPJ precision oncology 2024; (8(1)):180 doi:10.1038/s41698-024-00674-y.

Living with glioblastoma - the need for integrated support based on experiences of chaos, loss of autonomy, and isolation in both patients and their relatives.

Ståhl P, Henoch I, Rydenhag B, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2024; (32(9)):599 doi:10.1007/s00520-024-08801-y.

Deep learning-based end-to-end scan-type classification, pre-processing, and segmentation of clinical neuro-oncology studies.

Chakrabarty S, Abidi SA, Mousa M, et al.

Proceedings of SPIE--the International Society for Optical Engineering 2023; (12469()) doi:10.1117/12.2647656.

Central nervous system pediatric multi-disciplinary tumor board: a single center experience.

Russo R, Verdolotti T, Perna A, et al.

BMC cancer 2024; (24(1)):1146 doi:10.1186/s12885-024-12882-7.

Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma.

Valerius AR, Webb LM, Thomsen A, et al.

International journal of molecular sciences 2024; (25(19)) doi:10.3390/ijms251910570.

CAR T-cell therapy for gliomas.

Song KW, Scott BJ

Current opinion in neurology 2024; (37(6)):672-681 doi:10.1097/WCO.0000000000001318.

Implications of molecular classifications in glioma surgery.

Kalluri AL, Lee JH, Lucas CG, et al.

Journal of neuro-oncology 2025; (171(3)):559-569 doi:10.1007/s11060-024-04883-0.

Effects of Integrating Palliative Care in Patients With Advanced Cancer: A Systematic Review and Meta-Analysis of Quality of Life and Psychological Outcomes.

Bader H, Farraj H, Yamin S, et al.

The American journal of hospice & palliative care 2025; (42(10)):1061-1072 doi:10.1177/10499091241297924.

Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)-mutant astrocytoma may indicate radiation necrosis.

Ozeki Y, Honda-Kitahara M, Yanagisawa S, et al.

Japanese journal of clinical oncology 2025; (55(2)):106-112 doi:10.1093/jjco/hyae151.

Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers.

Varachev V, Susova O, Mitrofanov A, et al.

International journal of molecular sciences 2024; (25(23)) doi:10.3390/ijms252313004.

Clinical progress in the development of CAR T cells to treat malignant glioma.

Grewal EP, Nahed BV, Carter BS, et al.

Journal of neuro-oncology 2025; (171(3)):571-579 doi:10.1007/s11060-024-04909-7.

Spheno-Orbital Meningiomas: A Systematic Review of Treatment Modalities, Adjuvant Therapies, and Recurrence Risk.

Sulaiman II, Hassan Baker A, Shafeeq A, Ismail M

Cureus 2024; (16(11)):e73908 doi:10.7759/cureus.73908.

Identification of key elements in MRI reporting of intracranial meningiomas based on a nationwide survey of clinical experts in Germany.

Huckhagel T, Abboud T, Regelsberger J, et al.

Scientific reports 2025; (15(1)):1043 doi:10.1038/s41598-024-83737-1.

Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma.

Shah S, Nag A, Lucke-Wold B

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2025; (27(7)):2904-2912 doi:10.1007/s12094-025-03849-6.

Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: insights from the U.S. National Cancer Database.

Pham J, Cote DJ, Kang K, et al.

Journal of neuro-oncology 2025; (172(3)):655-665 doi:10.1007/s11060-025-04952-y.

Pediatric neurosurgery without pediatric neurosurgeons: a comparison of outcomes of pediatric brain tumor resections in Pakistan with a national US surgical database.

Abid H, Imran Y, Thobani H, et al.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2025; (41(1)):124 doi:10.1007/s00381-025-06775-8.

Palliative Care Need and Quality of Life Mediated by Psychological Distress in Neurologic Diseases.

Chan LML, Choi EPH, Lam WWT, et al.

Journal of pain and symptom management 2025; (69(6)):641-653.e3 doi:10.1016/j.jpainsymman.2025.03.004.

Canadian Expert Consensus Recommendations for the Diagnosis and Management of Glioblastoma: Results of a Delphi Study.

Mason WP, Harrison RA, Lapointe S, et al.

Current oncology (Toronto, Ont.) 2025; (32(4)) doi:10.3390/curroncol32040207.

Current trends in reoperation for recurrent glioblastoma: a meta-analysis (2007-2023).

Pichardo-Rojas PS, Garcia-Torrico F, Espinosa-Cantú CB, et al.

Journal of neuro-oncology 2025; (174(2)):271-301 doi:10.1007/s11060-025-05058-1.

The Prognostic Significance of Epidermal Growth Factor Receptor Amplification and Epidermal Growth Factor Receptor Variant III Mutation in Glioblastoma: A Systematic Review and Meta-Analysis with Implications for Targeted Therapy.

Zhu F, Qiu J, Ye H, et al.

International journal of molecular sciences 2025; (26(8)) doi:10.3390/ijms26083539.

Differentiation of tumor progression from pseudoprogression in glioblastoma patients with GRASP DCE-MRI and DSC-MRI.

Var V, Leu SM, Rommers N, et al.

Journal of neuroradiology = Journal de neuroradiologie 2025; (52(4)):101354 doi:10.1016/j.neurad.2025.101354.

Clinical and radiological features of pseudoprogression in brain tumors treated with immune checkpoint inhibitors.

Ibáñez-Juliá MJ, Bataller L, Cabello-Murgui FJ, et al.

Journal of neuro-oncology 2025; (174(3)):779-788 doi:10.1007/s11060-025-05091-0.

Efficacy of combined therapy with gamma knife radiosurgery and bevacizumab on survival outcomes in patients with recurrent high-grade glioma: a systematic review and meta-analysis.

Aghedi M, Larijani A, Bagheri AB, et al.

Neurosurgical review 2025; (48(1)):459.

Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial.

Bagley SJ, Desai AS, Fraietta JA, et al.

Nature medicine 2025; (31(8)):2778-2787 doi:10.1038/s41591-025-03745-0.

Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.

Li H, Wu Y, Chen Y, et al.

Acta neuropathologica communications 2025; (13(1)):126 doi:10.1186/s40478-025-02046-4.

Survival of a patient with glioblastoma multiforme after undergoing bone flap surgery followed by chemoradiotherapy to maintain tumor-treating fields: A case report.

Yang H, Wang L, Zheng J, et al.

The Journal of international medical research 2025; (53(6)):3000605251343020 doi:10.1177/03000605251343020.

RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology.

Sakata A, Fushimi Y, Oshima S, et al.

Japanese journal of radiology 2025; (43(10)):1557-1574 doi:10.1007/s11604-025-01821-6.

Glioblastoma at the crossroads: current understanding and future therapeutic horizons.

Singh S, Dey D, Barik D, et al.

Signal transduction and targeted therapy 2025; (10(1)):213 doi:10.1038/s41392-025-02299-4.

RANO 2.0: Update to the response assessment for gliomas.

Pineda Ibarra C, Oleaga Zufiria L, Valduvieco Ruiz I, et al.

Radiologia 2025; (67(4)):101621 doi:10.1016/j.rxeng.2025.101621.

Illuminating radiogenomic signatures in pediatric-type diffuse gliomas: insights into molecular, clinical, and imaging correlations. Part I: high-grade group.

Kurokawa R, Hagiwara A, Ueda D, et al.

La Radiologia medica 2025; (130(11)):1871-1887 doi:10.1007/s11547-025-02078-9.

Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma.

Zeyen T, Krause I, Decker A, et al.

Neuro-oncology 2026; (28(3)):790-801 doi:10.1093/neuonc/noaf261.

Enhanced Detection of EGFRvIII in Tumors: A Comparative Study of Split Read- and Read Depth-Based DNA Sequencing Approaches.

Chen N, Feng J, Wan D, et al.

The Journal of molecular diagnostics : JMD 2025; doi:10.1016/j.jmoldx.2025.11.002.

Palliative care interventions and outcome in patients with glioblastoma - a retrospective, single-center study.

Lind LM, Fischl A, Goettl E, et al.

BMC palliative care 2026; (25(1)):29 doi:10.1186/s12904-026-01987-4.

Differentiation of high-grade glioma and primary central nervous system lymphoma based on imaging heterogeneity scoring system.

Liu M, Li J, Xue C, et al.

Neurosurgical review 2026; (49(1)):145 doi:10.1007/s10143-025-03937-9.

Person-Centered Care in Glioblastoma: The Art of Early Advance Care Planning.

Serventi J, Mohile N

Cancers 2026; (18(3)) doi:10.3390/cancers18030413.

Tumor treating fields for newly diagnosed glioblastoma: a retrospective analysis.

Wang C, Xu H, Hu Y, et al.

Journal of neuro-oncology 2026; (177(1)):1.